Source: European Medicines Agency (EU) Revision Year: 2020 Publisher: Bristol-Myers Squibb Pharma EEIG, Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, D15 T867, Ireland
NULOJIX 250 mg powder for concentrate for solution for infusion.
| Pharmaceutical Form |
|---|
|
Powder for concentrate for solution for infusion (powder for concentrate). The powder is a white to off-white whole or fragmented cake. |
Each vial contains 250 mg of belatacept. After reconstitution, each ml of concentrate contains 25 mg belatacept.
Belatacept is a fusion protein produced in Chinese hamster ovary cells by recombinant DNA technology.
Excipient with known effect: Each vial contains 0.65 mmol sodium.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Belatacept |
Belatacept, a modified form of CTLA4-Ig, binds CD80 and CD86 more avidly than the parent CTLA4-Ig molecule from which it is derived. This increased avidity provides a level of immunosuppression that is necessary for preventing immune-mediated allograft failure and dysfunction. Belatacept blocks CD28 mediated co-stimulation of T cells inhibiting their activation. |
| List of Excipients |
|---|
|
Sucrose |
NULOJIX is supplied in a 20 ml vial (Type I flint glass) with a stopper (20 mm grey butyl rubber) and flip off seal (aluminum). Each vial is co-packaged with a disposable polypropylene syringe.
Pack sizes: 1 vial and 1 syringe or 2 vials and 2 syringes.
Not all pack-sizes may be marketed.
Bristol-Myers Squibb Pharma EEIG, Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, D15 T867, Ireland
EU/1/11/694/001-002
Date of first authorisation: 17 June 2011
Date of latest renewal: 18 February 2016
| Drug | Countries | |
|---|---|---|
| NULOJIX | Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Netherlands, Poland, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
